Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Real-Time Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal up18.920 +0.920 (+5.111%)

11/12/2019 17:22

CSPC Pharma (01093) tablets passes consistency evaluation

[ET Net News Agency, 11 December 2019] CSPC Pharmaceutical Group Limited (01093) said
"Ibuprofen Tablets (0.1g)" developed by CSPC Ouyi Pharmaceutical Co., Ltd., a subsidiary
of the Company, has been granted approval by the National Medical Products Administration
of the People's Republic of China for passing the consistency of quality and efficacy
evaluation of generic drugs.
Ibuprofen Tablets is an over-the-counter drug with analgesic and antipyretic effects,
and can be used for relieving mild to moderate pain such as headache, joint pain,
migraine, toothache, muscle pain, neuralgia, dysmenorrhea as well as fever caused by
common cold or influenza. (RC)

Remark: Real time quote last updated: 17/01/2020 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2020 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.